Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company. Our lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most common and aggressive form of primary brain cancer in adults. There are few treatment options for sufferers of GBM...See more
Headquarter Australia |
Countries of operation Australia |
Year founded 1994 (30 years) |
Funding status Publicly listed on stock exchange |
Company type MNC / Large Enterprise |
Quality Assurance Lead
Program Director
Share capital injection/new funding: approx. USD 1,300,000